You have followed a link to a page that does not exist yet. To create the page, start typing in the box below (see the help page for more info). If you are here by mistake, click your browser's back button.
Warning: You are recreating a page that was previously deleted.
You should consider whether it is appropriate to continue editing this page. The deletion and move log for this page are provided here for convenience:
- 14:18, 24 June 2024 Victor talk contribs deleted page National Cancer Center Dresden Trials (content was: "'''NCTID''': NCT03430843 '''Title''': A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma '''Study Summary''': The purpose of this study is to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that h...", and the only contributor was "Woloski" (talk))
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
